The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases
Objective: to study the efficacy and safety of the endothelin 1 receptor inhibitor traclir in patients with pulmonary hypertension (PH) asso ciated with systemic connective tissue diseases. Subjects and methods. The study include...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2011-12-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/653 |
| _version_ | 1826556124904554496 |
|---|---|
| author | Aleksandr Vitalyevich Volkov T V Martynyuk N N Yudkina N M Danilov T M Reshetnyak I E Chazova E L Nasonov |
| author_facet | Aleksandr Vitalyevich Volkov T V Martynyuk N N Yudkina N M Danilov T M Reshetnyak I E Chazova E L Nasonov |
| author_sort | Aleksandr Vitalyevich Volkov |
| collection | DOAJ |
| description | Objective: to study the efficacy and safety of the endothelin 1 receptor inhibitor traclir in patients with pulmonary hypertension (PH) asso ciated with systemic connective tissue diseases. Subjects and methods. The study included 4 patients: 3 with scleroderma systematica and 1 with exanthematous lupus erythematosus. The diagnosis of PH was established on the basis of right heart catheterization data and after exclusion of all its other causes of HP. In addition to hemodynamic evaluation, the female patients underwent echocardiography (EchoCG), lung function tests, 6-minute walk test, and blood biochemical study (determination of uric acid levels). Traclir was given in a dose of 62.5 mg twice in the first 4 weeks of the study and then in a dose of 125 mg twice for the subsequent 12 weeks. Every 4 weeks, the levels of transaminases were monitored and a pregnancy test was carried out in patients of fertile age. Results. After 16-week intake of the drug, all the female patients were found to have obvious positive changes as a longer 6-min walk test distance and two female patients had improvement in the functional class of PH. Estimation of hemodynamic parameters suggested a posi tive effect in all the female patients, as confirmed primarily by an increase in cardiac index and a reduction in pulmonary vascular resist ance. According to EchoCG data, there was a substantial increase in tricuspid annular plane systolic excursion; other parameters had no informative value. During traclir therapy, there was also an increase in lung diffusion capacity and a reduction in uric acid levels. There were no adverse events throughout the trial. Conclusion. Thus, the experience with traclir used in patients with PH associated with systemic autoimmune diseases suggests its high effi cacy and safety. |
| first_indexed | 2024-04-09T22:26:04Z |
| format | Article |
| id | doaj.art-428116a86bd745f3a7827c735b43276d |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2025-03-14T08:07:43Z |
| publishDate | 2011-12-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-428116a86bd745f3a7827c735b43276d2025-03-02T13:23:35ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922011-12-01496222710.14412/1995-4484-2011-515593The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseasesAleksandr Vitalyevich VolkovT V MartynyukN N YudkinaN M DanilovT M ReshetnyakI E ChazovaE L NasonovObjective: to study the efficacy and safety of the endothelin 1 receptor inhibitor traclir in patients with pulmonary hypertension (PH) asso ciated with systemic connective tissue diseases. Subjects and methods. The study included 4 patients: 3 with scleroderma systematica and 1 with exanthematous lupus erythematosus. The diagnosis of PH was established on the basis of right heart catheterization data and after exclusion of all its other causes of HP. In addition to hemodynamic evaluation, the female patients underwent echocardiography (EchoCG), lung function tests, 6-minute walk test, and blood biochemical study (determination of uric acid levels). Traclir was given in a dose of 62.5 mg twice in the first 4 weeks of the study and then in a dose of 125 mg twice for the subsequent 12 weeks. Every 4 weeks, the levels of transaminases were monitored and a pregnancy test was carried out in patients of fertile age. Results. After 16-week intake of the drug, all the female patients were found to have obvious positive changes as a longer 6-min walk test distance and two female patients had improvement in the functional class of PH. Estimation of hemodynamic parameters suggested a posi tive effect in all the female patients, as confirmed primarily by an increase in cardiac index and a reduction in pulmonary vascular resist ance. According to EchoCG data, there was a substantial increase in tricuspid annular plane systolic excursion; other parameters had no informative value. During traclir therapy, there was also an increase in lung diffusion capacity and a reduction in uric acid levels. There were no adverse events throughout the trial. Conclusion. Thus, the experience with traclir used in patients with PH associated with systemic autoimmune diseases suggests its high effi cacy and safety.https://rsp.mediar-press.net/rsp/article/view/653pulmonary hypertensionscleroderma systematicaexanthematous lupus erythematosusright heart catheterization6-minute walk test |
| spellingShingle | Aleksandr Vitalyevich Volkov T V Martynyuk N N Yudkina N M Danilov T M Reshetnyak I E Chazova E L Nasonov The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases Научно-практическая ревматология pulmonary hypertension scleroderma systematica exanthematous lupus erythematosus right heart catheterization 6-minute walk test |
| title | The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases |
| title_full | The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases |
| title_fullStr | The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases |
| title_full_unstemmed | The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases |
| title_short | The first Russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases |
| title_sort | first russian experience with the endothelin 1 receptor inhibitor traclir used in patients with pulmonary hypertension associated with systemic connective tissue diseases |
| topic | pulmonary hypertension scleroderma systematica exanthematous lupus erythematosus right heart catheterization 6-minute walk test |
| url | https://rsp.mediar-press.net/rsp/article/view/653 |
| work_keys_str_mv | AT aleksandrvitalyevichvolkov thefirstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT tvmartynyuk thefirstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT nnyudkina thefirstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT nmdanilov thefirstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT tmreshetnyak thefirstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT iechazova thefirstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT elnasonov thefirstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT aleksandrvitalyevichvolkov firstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT tvmartynyuk firstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT nnyudkina firstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT nmdanilov firstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT tmreshetnyak firstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT iechazova firstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases AT elnasonov firstrussianexperiencewiththeendothelin1receptorinhibitortraclirusedinpatientswithpulmonaryhypertensionassociatedwithsystemicconnectivetissuediseases |